Literature DB >> 23088974

Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy.

Misop Han1, Doyoung Chang, Chunwoo Kim, Brian J Lee, Yihe Zuo, Hyung-Joo Kim, Doru Petrisor, Bruce Trock, Alan W Partin, Ronald Rodriguez, H Ballentine Carter, Mohamad Allaf, Jongwon Kim, Dan Stoianovici.   

Abstract

PURPOSE: Transrectal ultrasound guided prostate biopsy results rely on physician ability to target the gland according to the biopsy schema. However, to our knowledge it is unknown how accurately the freehand, transrectal ultrasound guided biopsy cores are placed in the prostate and how the geometric distribution of biopsy cores may affect the prostate cancer detection rate.
MATERIALS AND METHODS: To determine the geometric distribution of cores, we developed a biopsy simulation system with pelvic mock-ups and an optical tracking system. Mock-ups were biopsied in a freehand manner by 5 urologists and by our transrectal ultrasound robot, which can support and move the transrectal ultrasound probe. We compared 1) targeting errors, 2) the accuracy and precision of repeat biopsies, and 3) the estimated significant prostate cancer (0.5 cm(3) or greater) detection rate using a probability based model.
RESULTS: Urologists biopsied cores in clustered patterns and under sampled a significant portion of the prostate. The robot closely followed the predefined biopsy schema. The mean targeting error of the urologists and the robot was 9.0 and 1.0 mm, respectively. Robotic assistance significantly decreased repeat biopsy errors with improved accuracy and precision. The mean significant prostate cancer detection rate of the urologists and the robot was 36% and 43%, respectively (p <0.0001).
CONCLUSIONS: Systematic biopsy with freehand transrectal ultrasound guidance does not closely follow the sextant schema and may result in suboptimal sampling and cancer detection. Repeat freehand biopsy of the same target is challenging. Robotic assistance with optimized biopsy schemas can potentially improve targeting, precision and accuracy. A clinical trial is needed to confirm the additional benefits of robotic assistance.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23088974      PMCID: PMC3876458          DOI: 10.1016/j.juro.2012.07.107

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion.

Authors:  Osamu Ukimura; Mihir M Desai; Suzanne Palmer; Samuel Valencerina; Mitchell Gross; Andre L Abreu; Monish Aron; Inderbir S Gill
Journal:  J Urol       Date:  2012-01-21       Impact factor: 7.450

2.  Robotic transperineal prostate biopsy: pilot clinical study.

Authors:  H Ho; J S P Yuen; P Mohan; E W Lim; C W S Cheng
Journal:  Urology       Date:  2011-09-21       Impact factor: 2.649

3.  Saturation biopsy of the prostate: why saturation does not saturate.

Authors:  Gianluca Giannarini; Riccardo Autorino; Giuseppe di Lorenzo
Journal:  Eur Urol       Date:  2009-03-25       Impact factor: 20.096

4.  Does the yield of prostate cancer biopsy and repeat biopsy justify the frequency of their use?

Authors:  Joseph Presti
Journal:  Nat Clin Pract Urol       Date:  2008-03-25

5.  Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer.

Authors:  D Svetec; K McCabe; S Peretsman; E Klein; H Levin; S Optenberg; I Thompson
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

6.  The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer.

Authors:  Al B Barqawi; Kyle O Rove; Saeed Gholizadeh; Colin I O'Donnell; Hari Koul; E David Crawford
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

7.  The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer.

Authors:  M Norberg; L Egevad; L Holmberg; P Sparén; B J Norlén; C Busch
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

Review 8.  Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.

Authors:  Sanoj Punnen; Robert K Nam
Journal:  Surg Oncol       Date:  2009-03-12       Impact factor: 3.279

9.  Beyond diagnosis: evolving prostate biopsy in the era of focal therapy.

Authors:  J L Dominguez-Escrig; S R C McCracken; D Greene
Journal:  Prostate Cancer       Date:  2010-12-09

10.  Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting.

Authors:  A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-09-29       Impact factor: 5.554

View more
  26 in total

1.  Robotic Transrectal Ultrasound Guided Prostate Biopsy.

Authors:  Sunghwan Lim; Changhan Jun; Doyoung Chang; Doru Petrisor; Misop Han; Dan Stoianovici
Journal:  IEEE Trans Biomed Eng       Date:  2019-01-07       Impact factor: 4.538

2.  Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms.

Authors:  N Westhoff; F P Siegel; D Hausmann; M Polednik; J von Hardenberg; M S Michel; M Ritter
Journal:  World J Urol       Date:  2016-11-09       Impact factor: 4.226

3.  System Integration and Preliminary Clinical Evaluation of a Robotic System for MRI-Guided Transperineal Prostate Biopsy.

Authors:  Niravkumar A Patel; Gang Li; Weijian Shang; Marek Wartenberg; Tamas Heffter; Everette C Burdette; Iulian Iordachita; Junichi Tokuda; Nobuhiko Hata; Clare M Tempany; Gregory S Fischer
Journal:  J Med Robot Res       Date:  2018-05-15

Review 4.  Robotic ultrasound and needle guidance for prostate cancer management: review of the contemporary literature.

Authors:  Deborah R Kaye; Dan Stoianovici; Misop Han
Journal:  Curr Opin Urol       Date:  2014-01       Impact factor: 2.309

5.  Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.

Authors:  Mitchell Kamrava; Amar U Kishan; Daniel J Margolis; Jiaoti Huang; Fred Dorey; Patricia Lieu; Patrick A Kupelian; Leonard S Marks
Journal:  Pract Radiat Oncol       Date:  2015-06-06

6.  MRI-Safe Robot for Endorectal Prostate Biopsy.

Authors:  Dan Stoianovici; Chunwoo Kim; Govindarajan Srimathveeravalli; Peter Sebrecht; Doru Petrisor; Jonathan Coleman; Stephen B Solomon; Hedvig Hricak
Journal:  IEEE ASME Trans Mechatron       Date:  2013-09-16       Impact factor: 5.303

7.  Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.

Authors:  Edward Chang; Tonye A Jones; Shyam Natarajan; Devi Sharma; Demetrios Simopoulos; Daniel J Margolis; Jiaoti Huang; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450

8.  MR Safe Robot, FDA Clearance, Safety and Feasibility Prostate Biopsy Clinical Trial.

Authors:  Dan Stoianovici; Chunwoo Kim; Doru Petrisor; Changhan Jun; Sunghwan Lim; Mark W Ball; Ashley Ross; Katarzyna J Macura; Mohamad Allaf
Journal:  IEEE ASME Trans Mechatron       Date:  2016-10-20       Impact factor: 5.303

9.  Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.

Authors:  Christopher P Filson; Shyam Natarajan; Daniel J A Margolis; Jiaoti Huang; Patricia Lieu; Frederick J Dorey; Robert E Reiter; Leonard S Marks
Journal:  Cancer       Date:  2016-01-07       Impact factor: 6.860

10.  Gleason underestimation is predicted by prostate biopsy core length.

Authors:  Leonardo O Reis; Brunno C F Sanches; Gustavo Borges de Mendonça; Daniel M Silva; Tiago Aguiar; Ocivaldo P Menezes; Athanase Billis
Journal:  World J Urol       Date:  2014-08-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.